cilostazol has been researched along with Sclerosis, Systemic in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cilostazol is a selective inhibitor of phosphodiesterase-III with antiplatelet, antithrombotic and vasodilating properties." | 1.43 | Efficacy of cilostazol for the treatment of Raynaud's phenomenon in systemic sclerosis patients. ( Filaci, G; Indiveri, F; Negrini, S; Penza, E; Puppo, F; Rollando, D; Spanò, F, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Negrini, S | 1 |
| Spanò, F | 1 |
| Penza, E | 1 |
| Rollando, D | 1 |
| Indiveri, F | 1 |
| Filaci, G | 1 |
| Puppo, F | 1 |
1 other study available for cilostazol and Sclerosis, Systemic
| Article | Year |
|---|---|
Efficacy of cilostazol for the treatment of Raynaud's phenomenon in systemic sclerosis patients.
Topics: Adult; Aged; Cilostazol; Controlled Before-After Studies; Humans; Middle Aged; Raynaud Disease; Scle | 2016 |